^
Association details:
| Biomarker: | ER mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor, mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).
Published date:
05/13/2020
Excerpt:
Pt tumor tissue analysis (n = 25) confirmed pts with FGF3/4/19 amplification (n = 4) had larger changes in tumor size in response to G+P+L/F (p = 0.029). Of the 6 pts with an ESR1 mutation, 1 pt with an ESR1 Y537S mutation exhibited a partial response (PR) to G+P+L.
Secondary therapy:
letrozole
DOI:
10.1200/JCO.2020.38.15_suppl.1052
Trial ID:
Source:
Title:
Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009).
Published date:
05/16/2018
Excerpt:
Preliminary stable disease/partial response: G+P+L: 53%/33%; G+P+F: 55%/20%....G can be combined with P+L or P+F with manageable toxicity and promising preliminary antitumor activity.
Secondary therapy:
fulvestrant; letrozole
DOI:
10.1200/JCO.2018.36.15_suppl.1040
Trial ID:
